Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy: Results of 2 phase II studies

Robin L. Thurmond, Andrew Greenspan, Waldemar Radziszewski, Xie L. Xu, Ye Miao, Bin Chen, Ting Ting Ge, Bei Zhou, Daniel G. Baker, Dace Pavlova, Christopher T. Ritchlin, Yoshiya Tanaka, Tsutomu Takeuchi, Josef S. Smolen

研究成果: Article査読

9 被引用数 (Scopus)

抄録

Objective. To assess toreforant (selective histamine H4 receptor antagonist) in active rheumatoid arthritis (RA). Methods. In a phase IIa, double-blind, placebo-controlled test, 86 patients were randomized (2:1) to once-daily toreforant 100 mg or placebo for 12 weeks. In phase IIb, double-blind, placebo-controlled, dose-range-finding evaluations, 272 patients were randomized (1:1:1:1) to once-daily placebo or toreforant 3/10/30 mg. Primary efficacy endpoints for both studies were Week 12 changes in 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP). Results. Phase IIa testing was terminated prematurely (patient fatality; secondary hemophagocytic lymphohistiocytosis). Posthoc analyses indicated toreforant 100 mg/day reduced RA signs/symptoms through Week 12. Phase IIb testing, however, showed no significant Week 12 improvement in DAS28-CRP with toreforant. Conclusion. Toreforant was not effective in phase IIb testing.

本文言語English
ページ(範囲)1637-1642
ページ数6
ジャーナルJournal of Rheumatology
43
9
DOI
出版ステータスPublished - 2016 9

ASJC Scopus subject areas

  • 免疫アレルギー学
  • リウマチ学
  • 免疫学

フィンガープリント

「Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy: Results of 2 phase II studies」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル